MedTrace Logo

Role of Pentoxifylline as an Adjuvant Therapy for Adult Patients With Major Depressive Disorder

NCT03554447 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 80

Last updated 2020-06-16

No results posted yet for this study

Summary

This study aimed to evaluate the therapeutic benefits of pentoxifylline (PTX) in treatment of adult patients with MDD as it has anti-inflammatory and phosphodiastrase inhibition activities.

Conditions

Interventions

DRUG

Escitalopram 20 mg tablet plus Pentoxifylline 400Mg Tablet

Selective serotonin reuptake inhibitor plus phosphodiesterase inhibitor with anti-inflammatory properties

DRUG

Escitalopram 20 mg tablet + Placebo

Selective serotonin reuptake inhibitor plus placebo

Sponsors & Collaborators

  • Mahmoud Samy Abdallah

    lead OTHER

Principal Investigators

  • Sahar El-Haggar, Ph.D · Tanta University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-04-20
Primary Completion
2017-12-01
Completion
2018-12-31

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03554447 on ClinicalTrials.gov